Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| European Institute of Oncology | OTHER |
Not provided
Not provided
Not provided
The aim of the study is to evaluate the efficacy of a dermocosmetic protocol in reducing the main cutaneous side effects that occur in palmar-plantar erythrodysesthesia syndrome in subjects with a tumor diagnosis, undergoing chemotherapy and targeted treatments such as target therapy and radiotherapy.
Cancer patients undergoing active oncological treatment (chemotherapy, biological therapies, radiotherapy) experience multiple side effects, including skin toxicity, which negatively affects their quality of life, increasing the risk of interrupting cancer therapy. Symptomatic therapy is often neglected and prescribed late in the course of the disease. Many patients undergoing anti-cancer therapies experience adverse skin reactions such as dry skin, rashes, redness, and itching. Dry skin, erythema, and nail lesions are particularly common for those undergoing chemotherapy and targeted treatments such as target therapy and radiotherapy.
Cleansing must be done by affinity, that is, with an emulsification mechanism and not solubilization, through the use of "sebum-like" fatty substances to remove only the excess lipids on the skin surface and the dirt attached to them. This eudermic cleansing without the use of surfactants does not solubilize the epidermal lipids that are fundamental in the structure of the hydrolipidic film, maintaining the right protection and hydration of the skin.
Therefore, the main objective of the following study is to evaluate the efficacy of 4 topical cosmetic products specifically formulated for patients undergoing oncological therapy in the management of palmar-plantar erythrodysesthesia syndrome, a skin toxicity typical of oncological treatments, which causes skin alterations such as erythema and/or xerosis and/or mild to moderate nail damage, to ensure an improvement of the skin condition during therapy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Diagnosed cancer patients receiving different therapies with hand-foot syndrome skin side effects | Participants were diagnosed cancer patients receiving chemotherapy and targeted or hormonal treatments. Recruitment was performed by the medical oncologists based on the presence of Hand-foot syndrome (HFS) grade 1 symptoms. The severity of HFS was graded according to the The National Cancer Institute-Common Terminology Criteria for Adverse Events Criteria (NCI-CTCAE) version 5.0. All patients enrolled were provided with a kit of four cosmetic products formulated explicitly for cancer skincare |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| cosmetic products | Other | All patients enrolled were prescribed four cosmetic products (Ontherapy® by Dermophisiologique) for skin treatment: a cleansing cream, a soothing and nourishing cream, an anti-desquamation cream with urea 5%, and an emollient mixture. Patients were instructed to use each product at home for 45 days, following a specific protocol: in the morning, apply the affinity cleansing cream during skin cleansing, followed by the anti-desquamation cream, while in the evening, apply affinity cleansing cream followed by the application of the emollient mixture and then the soothing and nourishing cream. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in the mean skin hydration index at 45 days | Changes from the baseline of skin hydration were assessed using a Corneometer® CM 825 probe that analyze water related changes in the skin's electrical capacitance. All measurements reported are the average of three assessments obtained on two skin areas: the right hand 's dorsum and the right foot's dorsum | Baseline and 45 days |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in the mean skin redness index at 45 days | Changes from the baseline of skin redness (erythema) were measured photometrically by a Mexameter ® MX 18 30 32 All measurements reported are the average of three assessments obtained on four skin areas: the palm of the right hand, fingertip of the right hand, sole of the right foot and fingertip of the right foot. | Baseline and 45 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Participants were diagnosed cancer patients recruited from the oncology departments at the European Institute of Oncology, Milan, Italy.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ida Minchella | European Institute of Oncology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| European Institute of Oncology (IEO) | Milan | Milan | 20141 | Italy |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29527024 | Background | Biswal SG, Mehta RD. Cutaneous Adverse Reactions of Chemotherapy in Cancer Patients: A Clinicoepidemiological Study. Indian J Dermatol. 2018 Jan-Feb;63(1):41-46. doi: 10.4103/ijd.IJD_65_17. | |
| 35867950 | Background | Saadet ED, Tek I. Evaluation of chemotherapy-induced cutaneous side effects in cancer patients. Int J Dermatol. 2022 Dec;61(12):1519-1526. doi: 10.1111/ijd.16361. Epub 2022 Jul 22. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D060831 | Hand-Foot Syndrome |
| ID | Term |
|---|---|
| D003875 | Drug Eruptions |
| D003872 | Dermatitis |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D003358 | Cosmetics |
| ID | Term |
|---|---|
| D020313 | Specialty Uses of Chemicals |
| D020164 | Chemical Actions and Uses |
| D006795 | Household Products |
| D013676 | Technology, Industry, and Agriculture |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Change from Baseline in the mean overall Skindex-16 score at 45 days | The impact of skin manifestations on patient Quality of life (QoL) was evaluated using the Skindex 16, a 16 item self report questionnaire. It is composed of three subscales: perceived symptoms (items 1-5), emotions (items 6-11), and daily functions (items 12-16).Responses to each item were transformed into a linear scale of 100, varying from 0 (never bothered) to 100 (corresponding to 6, always bothered). Each raw score was then normalized for the statistical to 100 (corresponding to 6, always bothered). Each raw score was then normalized for the statistical analysis. The final score is the average of the patient's responses in each domain. | Baseline and 45 days |
| Assessment from baseline of compliance with the study protocol at 45 days | The compliance of patients with the product use protocol was assessed through a specific diary within 45 days, divided into morning and evening, containing two boxes to tick (YES for products applied or NO for products not applied). Additionally, there is a NOTES section where the patient can input the reason for not applying the product | Baseline and 45 days |
| Change in the degree of toxicity of hand-foot syndrome using the v5.0 scale of the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE). | The oncologist and dermatologist clinically evaluated HFS severity by comparing patient pictures taken standardized at baseline and at the end of the study (45 days) on four body areas: the back of the hand, the back of the foot, the palm, and the sole. The oncologist assessed the change in the degree of hand-foot syndrome toxicity using the National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 scale. The dermatologist used a three-point evaluation (improvement, stability, worsening) to assess the change in HFS-related skin symptoms (erythema, xerosis, and desquamation). Treatment benefit was evaluated according to the reduction of the NCI CTCAE grade and the improvement of skin symptoms. | Baseline and 45 days |
| D004342 |
| Drug Hypersensitivity |
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| D064419 | Chemically-Induced Disorders |